MXPA05009367A - Antagonistas del receptor opioide. - Google Patents
Antagonistas del receptor opioide.Info
- Publication number
- MXPA05009367A MXPA05009367A MXPA05009367A MXPA05009367A MXPA05009367A MX PA05009367 A MXPA05009367 A MX PA05009367A MX PA05009367 A MXPA05009367 A MX PA05009367A MX PA05009367 A MXPA05009367 A MX PA05009367A MX PA05009367 A MXPA05009367 A MX PA05009367A
- Authority
- MX
- Mexico
- Prior art keywords
- receptor antagonists
- opioid receptor
- racemate
- diastereomer
- enantiomer
- Prior art date
Links
- 229940123257 Opioid receptor antagonist Drugs 0.000 title 1
- 239000000203 mixture Substances 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/34—Oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/58—One oxygen atom, e.g. butenolide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/30—Hetero atoms other than halogen
- C07D333/32—Oxygen atoms
Abstract
Se describen un compuesto de formula I: (I) en el que las variables son como se describen en la presente memoria, o una de sus sales, solvatos, enantiomeros, racematos, diastereoisomeros o mezclas de los mismos farmaceuticamente aceptables, formulaciones y procedimientos de uso de los mismos (ver formula (I)).
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US45324303P | 2003-03-07 | 2003-03-07 | |
PCT/US2004/003368 WO2004080996A1 (en) | 2003-03-07 | 2004-03-01 | Opioid receptor antagonists |
Publications (1)
Publication Number | Publication Date |
---|---|
MXPA05009367A true MXPA05009367A (es) | 2005-11-04 |
Family
ID=32990743
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MXPA05009367A MXPA05009367A (es) | 2003-03-07 | 2004-03-01 | Antagonistas del receptor opioide. |
Country Status (12)
Country | Link |
---|---|
US (1) | US7396943B2 (es) |
EP (1) | EP1606275B1 (es) |
JP (1) | JP2006519855A (es) |
CN (1) | CN1753884A (es) |
AT (1) | ATE406360T1 (es) |
AU (1) | AU2004220113A1 (es) |
BR (1) | BRPI0408108A (es) |
CA (1) | CA2513791A1 (es) |
DE (1) | DE602004016127D1 (es) |
ES (1) | ES2312972T3 (es) |
MX (1) | MXPA05009367A (es) |
WO (1) | WO2004080996A1 (es) |
Families Citing this family (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0217757D0 (en) | 2002-07-31 | 2002-09-11 | Glaxo Group Ltd | Novel compounds |
CN1305852C (zh) * | 2002-09-19 | 2007-03-21 | 伊莱利利公司 | 作为阿片受体拮抗剂的二芳基醚 |
ES2527870T5 (es) | 2003-04-08 | 2022-10-14 | Progenics Pharm Inc | Formulaciones farmacéuticas que contienen metilnaltrexona |
WO2004092167A1 (en) * | 2003-04-09 | 2004-10-28 | Millennium Pharmaceuticals, Inc. | Beta-carbolines useful for treating inflammatory disease |
BRPI0417156A (pt) | 2003-12-12 | 2007-03-06 | Lilly Co Eli | composto, composição farmacêutica, e, métodos para bloquear receptor mu, capa, delta ou combinação (heterodìmero) dos mesmos em mamìferos, para tratar e/ou prevenir doenças relacionadas com obesidade e obesidade, para suprimir apetite em um paciente, para efetuar perda de peso em um paciente obeso |
CN1894240A (zh) * | 2003-12-22 | 2007-01-10 | 伊莱利利公司 | 阿片受体拮抗剂 |
GB0402140D0 (en) * | 2004-01-30 | 2004-03-03 | Smithkline Beecham Corp | Novel compounds |
GB0402137D0 (en) * | 2004-01-30 | 2004-03-03 | Smithkline Beecham Corp | Novel compounds |
GB0402143D0 (en) * | 2004-01-30 | 2004-03-03 | Smithkline Beecham Corp | Novel compounds |
JP2007528898A (ja) | 2004-03-12 | 2007-10-18 | イーライ リリー アンド カンパニー | オピオイド受容体拮抗物質 |
ES2347577T3 (es) | 2004-03-12 | 2010-11-02 | Eli Lilly And Company | Antagonistas de receptores opioides. |
DE602005012380D1 (de) | 2004-03-15 | 2009-03-05 | Lilly Co Eli | 4-(5-(aminomethyl)-indol-1-ylmethyl)benzamidderivate und verwandte verbindungen als opioidrezeptorantagonisten zur behandlung von fettleibigkeit |
EP1735268B1 (en) | 2004-03-15 | 2012-02-15 | Eli Lilly And Company | Opioid receptor antagonists |
WO2006076706A1 (en) | 2005-01-14 | 2006-07-20 | Millennium Pharmaceuticals, Inc. | Cinnamide and hydrocinnamide derivatives with raf-kinase inhibitory activity |
US8518962B2 (en) | 2005-03-07 | 2013-08-27 | The University Of Chicago | Use of opioid antagonists |
US9662325B2 (en) | 2005-03-07 | 2017-05-30 | The University Of Chicago | Use of opioid antagonists to attenuate endothelial cell proliferation and migration |
WO2006096626A2 (en) * | 2005-03-07 | 2006-09-14 | The University Of Chicago | Use of opioid antagonists to attenuate endothelial cell proliferation and migration |
US8524731B2 (en) * | 2005-03-07 | 2013-09-03 | The University Of Chicago | Use of opioid antagonists to attenuate endothelial cell proliferation and migration |
AR057035A1 (es) | 2005-05-25 | 2007-11-14 | Progenics Pharm Inc | SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS |
AR057325A1 (es) | 2005-05-25 | 2007-11-28 | Progenics Pharm Inc | Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos |
CN101331120A (zh) | 2005-10-13 | 2008-12-24 | 史密丝克莱恩比彻姆公司 | 作为阿片样物质受体调节剂的酚醚化合物 |
KR20090051778A (ko) * | 2006-09-08 | 2009-05-22 | 화이자 프로덕츠 인코포레이티드 | 다이아릴 에터 유도체 및 이의 용도 |
TWI466671B (zh) | 2007-03-29 | 2015-01-01 | Progenics Pharm Inc | 末梢性類鴉片受體拮抗劑及其用途 |
EP3263571B2 (en) | 2007-03-29 | 2023-08-23 | Progenics Pharmaceuticals, Inc. | Crystal form of (r)-n-methylnaltrexone bromide and uses thereof |
MX2009010515A (es) | 2007-03-29 | 2009-10-19 | Wyeth Corp | Antagonistas del receptor opioide periferico y usos de los mismos. |
WO2008142454A1 (en) | 2007-05-22 | 2008-11-27 | Prosidion Limited | Bicyclic aryl and heteroaryl compounds for the treatment of metabolic disorders |
JP2010538055A (ja) | 2007-09-07 | 2010-12-09 | プロシディオン・リミテッド | 二環式アリールおよびヘテロアリール受容体モジュレーター |
TWI422369B (zh) * | 2008-01-22 | 2014-01-11 | Lilly Co Eli | κ選擇性類鴉片受體拮抗劑 |
CN101959892B (zh) | 2008-02-06 | 2014-01-08 | 普罗热尼奇制药公司 | (r),(r)-2,2’-二-甲基纳曲酮的制备和用途 |
EP2278966B1 (en) | 2008-03-21 | 2019-10-09 | The University of Chicago | Treatment with opioid antagonists and mtor inhibitors |
CA2676881C (en) | 2008-09-30 | 2017-04-25 | Wyeth | Peripheral opioid receptor antagonists and uses thereof |
JP2012518651A (ja) * | 2009-02-23 | 2012-08-16 | マリンクロッド インコーポレイテッド | (+)−モルフィナニウムn−オキシドおよびそれらの生成方法 |
KR20120092592A (ko) * | 2009-09-18 | 2012-08-21 | 아돌로 코포레이션 | 위장관 질환을 위한 오피오이드 수용체 길항제의 용도 |
WO2012051502A1 (en) * | 2010-10-14 | 2012-04-19 | University Of Utah Research Foundation | Methods and compositions related to neuroactive thiazoline compounds |
CN106117195A (zh) * | 2016-06-09 | 2016-11-16 | 青岛辰达生物科技有限公司 | 一种用于治疗白血病的药物达沙替尼的合成方法 |
US10316021B2 (en) | 2016-11-28 | 2019-06-11 | Pfizer Inc. | Heteroarylphenoxy benzamide kappa opioid ligands |
CN112341404B (zh) * | 2019-08-09 | 2023-05-23 | 成都苑东生物制药股份有限公司 | 噻唑类衍生物或盐、异构体、其制备方法及用途 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4891379A (en) * | 1987-04-16 | 1990-01-02 | Kabushiki Kaisha Kobe Seikosho | Piperidine opioid antagonists |
AUPP796798A0 (en) | 1998-12-30 | 1999-01-28 | Fujisawa Pharmaceutical Co., Ltd. | New compound |
CA2433018A1 (en) | 2000-12-21 | 2002-06-27 | Joel C. Barrish | Thiazolyl inhibitors of tec family tyrosine kinases |
PT1379239E (pt) | 2001-03-29 | 2007-12-06 | Lilly Co Eli | N- (2-ariletil)benzilaminas como antagonistas do receptor 5-ht6 |
-
2004
- 2004-03-01 AU AU2004220113A patent/AU2004220113A1/en not_active Abandoned
- 2004-03-01 WO PCT/US2004/003368 patent/WO2004080996A1/en active Application Filing
- 2004-03-01 ES ES04716082T patent/ES2312972T3/es not_active Expired - Lifetime
- 2004-03-01 JP JP2006508678A patent/JP2006519855A/ja not_active Withdrawn
- 2004-03-01 AT AT04716082T patent/ATE406360T1/de not_active IP Right Cessation
- 2004-03-01 US US10/544,286 patent/US7396943B2/en not_active Expired - Fee Related
- 2004-03-01 CN CNA2004800050293A patent/CN1753884A/zh active Pending
- 2004-03-01 MX MXPA05009367A patent/MXPA05009367A/es unknown
- 2004-03-01 BR BRPI0408108-0A patent/BRPI0408108A/pt not_active Application Discontinuation
- 2004-03-01 DE DE602004016127T patent/DE602004016127D1/de not_active Expired - Lifetime
- 2004-03-01 EP EP04716082A patent/EP1606275B1/en not_active Expired - Lifetime
- 2004-03-01 CA CA002513791A patent/CA2513791A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
JP2006519855A (ja) | 2006-08-31 |
US7396943B2 (en) | 2008-07-08 |
ATE406360T1 (de) | 2008-09-15 |
WO2004080996A1 (en) | 2004-09-23 |
EP1606275A1 (en) | 2005-12-21 |
ES2312972T3 (es) | 2009-03-01 |
BRPI0408108A (pt) | 2006-03-01 |
DE602004016127D1 (de) | 2008-10-09 |
CA2513791A1 (en) | 2004-09-23 |
US20060166987A1 (en) | 2006-07-27 |
AU2004220113A1 (en) | 2004-09-23 |
CN1753884A (zh) | 2006-03-29 |
EP1606275B1 (en) | 2008-08-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MXPA05009367A (es) | Antagonistas del receptor opioide. | |
MXPA05009508A (es) | Derivados de nicotinamida 6-substituida como antagonistas de receptor opioide. | |
AU2003239389A1 (en) | Opioid receptor antagonists | |
MXPA05003093A (es) | Diaril eteres como antagonistas de receptor opiode. | |
TW200714583A (en) | Substituted gamma lactams as therapeutic agents | |
WO2004000808A3 (en) | N-substituted piperidine derivatives as serotonin receptor agents | |
IL173530A0 (en) | Nonsedating a-2 agonisti-(2,3-dimethyl-phenyl)-ethyl-1,3-dihydro-imizadole-2-thione | |
ATE475640T1 (de) | Antagonisten des opioidrezeptors | |
IL157254A0 (en) | N-substituted nonaryl-heterocyclic nmda/mr2b antagonists | |
WO2002074758A3 (en) | Novel amines as histamine-3 receptor ligands and their therapeutic applications | |
MXPA05012678A (es) | Forma cristalina del agonista del receptor adrenergico beta2. | |
WO2006052798A3 (en) | Method of treating pathological blushing | |
WO2004082623A3 (en) | Substituted piperidine compounds | |
CA2511255A1 (en) | 2-piperidone derivatives as prostaglandin agonists | |
MXPA05013474A (es) | Derivados de quinolilamida como antagonistas de ccr-5. | |
MXPA04010625A (es) | Antagonista de receptor de taquicinina. | |
UA95223C2 (ru) | Производные пиридопиримидина, их получение, их применение в терапии | |
CA2463264A1 (en) | 3-azabicyclo (3.1.0) hexane derivatives as opioid receptor antagonists | |
RS98704A (en) | New pharmaceutical compositions containing flibanserin polymorpha | |
JO2413B1 (en) | Benzoxazine derivatives and their use | |
WO2004112704A3 (en) | Substituted piperidine compounds and methods of their use | |
WO2004111008A3 (en) | Use of a compound of formula i for making a pharmaceutical composition | |
EP1617806A4 (en) | SELECTIVE SPIROCYCLIC GLUCOCORTICOID RECEPTOR MODULATORS | |
PT1414453E (pt) | Polimorfo de cloridrato de fexofenadina | |
MY139228A (en) | Imidazolinylmethyl aralkylsulfonamides |